Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06QRW
|
|||
| Former ID |
DIB003873
|
|||
| Drug Name |
Lazabemide
|
|||
| Synonyms |
103878-84-8; Ro-19-6327; N-(2-Aminoethyl)-5-chloropicolinamide; CCRIS 7301; UNII-420HD787N9; N-(2-aminoethyl)-5-chloropyridine-2-carboxamide; Ro 19-6327 hydrate; CHEMBL279390; Ro 19-6327/000; 420HD787N9; C8H10ClN3O; 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide; NCGC00167737-01; Lazabemide [USAN:INN]; Lazabemide [USAN:INN:BAN]; Lazabemine; Pakio; Tempium; Ro-41-3776; Ro-19-6327/000; LAZEBEMIDE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Skin imperfections [ICD-11: EK71; ICD-10: L91.8] | Patented | [1] | |
| Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Discontinued in Phase 3 | [2], [3] | ||
| Company |
Roche Holding AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H10ClN3O
|
|||
| Canonical SMILES |
C1=CC(=NC=C1Cl)C(=O)NCCN
|
|||
| InChI |
1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)
|
|||
| InChIKey |
JZXRLKWWVNUZRB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 103878-84-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980091, 8194561, 15220005, 43127665, 47206517, 50064090, 50112873, 50460487, 57318127, 92729659, 103183900, 103831836, 103938836, 104350168, 117465703, 126424309, 128351763, 132555187, 134343054, 135028045, 137239417, 139290484, 139640715, 164814824, 178103253, 179149503, 184545911, 198970494, 224982470, 226493370, 252216705, 252351209, 252428934
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6640). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004032) | |||
| REF 4 | The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37. | |||
| REF 5 | Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.